Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis
Background. Non-alcoholic steatohepatitis (NASH) in individuals with type 2 diabetes mellitus (T2DM) is considered a comorbid condition with an unfavorable prognosis and a significant economic burden on the global healthcare system. Despite patient-centered treatment goals and the coordinated effor...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaslavsky O.Yu.
2024-09-01
|
| Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
| Subjects: | |
| Online Access: | https://iej.zaslavsky.com.ua/index.php/journal/article/view/1423 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221742253309952 |
|---|---|
| author | N.M. Protas I.O. Kostitska M.V. Bielinskyi |
| author_facet | N.M. Protas I.O. Kostitska M.V. Bielinskyi |
| author_sort | N.M. Protas |
| collection | DOAJ |
| description | Background. Non-alcoholic steatohepatitis (NASH) in individuals with type 2 diabetes mellitus (T2DM) is considered a comorbid condition with an unfavorable prognosis and a significant economic burden on the global healthcare system. Despite patient-centered treatment goals and the coordinated efforts of a multidisciplinary team of physicians, a significant proportion of patients fail to achieve glycemic control, indicating the complex and multifactorial pathogenesis of T2DM. Achieving glycemic targets with a hepatocentric approach should be considered an alternative way to improve the treatment algorithm for patients with T2DM and NASH. The purpose of the study was to evaluate the hepatoprotective effect of dapagliflozin on achieving glycemic control in individuals with T2DM and NASH. Materials and methods. Sixty patients with T2DM and NASH were examined and divided into two groups based on antidiabetic therapy: group I (n = 30) received basic medical therapy (BMT) which included metformin (2000 mg/day), alpha-lipoic acid (600 mg/day), and rosuvastatin (10 mg/day) in combination with insulin therapy; group II (n = 30) received BMT in combination with dapagliflozin at a daily dose of 10 mg. All patients underwent comprehensive laboratory tests, including calculations of non-invasive screening biomarkers (HEPAmet fibrosis score) and liver fibrosis severity (Fibrosis-4 index, FIB-4), as well as clinical and instrumental diagnostics using liver shear wave elastography (METAVIR, kPa). The study period lasted 12 weeks. Results. After 3 months of treatment, group I showed a tendency toward normalization of glycemic control parameters, while the level of glycated hemoglobin significantly decreased (∆ –22.92 %, p < 0.001) in group II. Throughout the study period, no episodes of hypoglycemia or adverse events were reported. The effectiveness of the additional administration of dapagliflozin supports the hepatocentric approach to achieving glycemic control with normalization of fibrosis markers (HEPAmet: AUC 0.828 (95% CI: 0.712–0.943, p < 0.001); FIB-4: AUC 0.765 (95% CI: 0.643–0.887, p < 0.001)) and a significant reduction of METAVIR scores (AUC 0.996 (95% CI: 0.986–1.005, p < 0.001)) according to liver shear wave elastography. Conclusions. The study results indicate that administration of dapagliflozin at a dose of 10 mg/day with BMT effectively impacts glycemic control and activates additional hepatoprotective mechanisms in patients with T2DM and NASH. A hepatocentric approach to the safe and effective management of T2DM in individuals with NASH is justified by the timely use of an updated treatment algorithm with an emphasis on sodium-glucose cotransporter 2 inhibitors. |
| format | Article |
| id | doaj-art-a385e9590f8b4d7e9d7f28f1d3db35c8 |
| institution | Kabale University |
| issn | 2224-0721 2307-1427 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Zaslavsky O.Yu. |
| record_format | Article |
| series | Mìžnarodnij Endokrinologìčnij Žurnal |
| spelling | doaj-art-a385e9590f8b4d7e9d7f28f1d3db35c82024-11-10T19:11:12ZengZaslavsky O.Yu.Mìžnarodnij Endokrinologìčnij Žurnal2224-07212307-14272024-09-0120537538210.22141/2224-0721.20.5.2024.14231421Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitisN.M. Protas0https://orcid.org/0009-0004-3192-0413I.O. Kostitska1https://orcid.org/0000-0003-4319-0986M.V. Bielinskyi2https://orcid.org/0000-0001-5013-3838Communal Non-Commercial Enterprise “Regional Clinical Hospital of Ivano-Frankivsk Regional Council”, Ivano-Frankivsk, Ukraine; Ivano-Frankivsk National Medical University, Ivano-Frankivsk, UkraineIvano-Frankivsk National Medical University, Ivano-Frankivsk, UkraineIvano-Frankivsk National Medical University, Ivano-Frankivsk, UkraineBackground. Non-alcoholic steatohepatitis (NASH) in individuals with type 2 diabetes mellitus (T2DM) is considered a comorbid condition with an unfavorable prognosis and a significant economic burden on the global healthcare system. Despite patient-centered treatment goals and the coordinated efforts of a multidisciplinary team of physicians, a significant proportion of patients fail to achieve glycemic control, indicating the complex and multifactorial pathogenesis of T2DM. Achieving glycemic targets with a hepatocentric approach should be considered an alternative way to improve the treatment algorithm for patients with T2DM and NASH. The purpose of the study was to evaluate the hepatoprotective effect of dapagliflozin on achieving glycemic control in individuals with T2DM and NASH. Materials and methods. Sixty patients with T2DM and NASH were examined and divided into two groups based on antidiabetic therapy: group I (n = 30) received basic medical therapy (BMT) which included metformin (2000 mg/day), alpha-lipoic acid (600 mg/day), and rosuvastatin (10 mg/day) in combination with insulin therapy; group II (n = 30) received BMT in combination with dapagliflozin at a daily dose of 10 mg. All patients underwent comprehensive laboratory tests, including calculations of non-invasive screening biomarkers (HEPAmet fibrosis score) and liver fibrosis severity (Fibrosis-4 index, FIB-4), as well as clinical and instrumental diagnostics using liver shear wave elastography (METAVIR, kPa). The study period lasted 12 weeks. Results. After 3 months of treatment, group I showed a tendency toward normalization of glycemic control parameters, while the level of glycated hemoglobin significantly decreased (∆ –22.92 %, p < 0.001) in group II. Throughout the study period, no episodes of hypoglycemia or adverse events were reported. The effectiveness of the additional administration of dapagliflozin supports the hepatocentric approach to achieving glycemic control with normalization of fibrosis markers (HEPAmet: AUC 0.828 (95% CI: 0.712–0.943, p < 0.001); FIB-4: AUC 0.765 (95% CI: 0.643–0.887, p < 0.001)) and a significant reduction of METAVIR scores (AUC 0.996 (95% CI: 0.986–1.005, p < 0.001)) according to liver shear wave elastography. Conclusions. The study results indicate that administration of dapagliflozin at a dose of 10 mg/day with BMT effectively impacts glycemic control and activates additional hepatoprotective mechanisms in patients with T2DM and NASH. A hepatocentric approach to the safe and effective management of T2DM in individuals with NASH is justified by the timely use of an updated treatment algorithm with an emphasis on sodium-glucose cotransporter 2 inhibitors.https://iej.zaslavsky.com.ua/index.php/journal/article/view/1423type 2 diabetes mellitusnon-alcoholic steatohepatitissodium-glucose cotransporter 2 inhibitorsdapagliflozin |
| spellingShingle | N.M. Protas I.O. Kostitska M.V. Bielinskyi Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis Mìžnarodnij Endokrinologìčnij Žurnal type 2 diabetes mellitus non-alcoholic steatohepatitis sodium-glucose cotransporter 2 inhibitors dapagliflozin |
| title | Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis |
| title_full | Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis |
| title_fullStr | Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis |
| title_full_unstemmed | Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis |
| title_short | Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis |
| title_sort | hepatocentric approach to achieving compensation of diabetes mellitus in people with non alcoholic steatohepatitis |
| topic | type 2 diabetes mellitus non-alcoholic steatohepatitis sodium-glucose cotransporter 2 inhibitors dapagliflozin |
| url | https://iej.zaslavsky.com.ua/index.php/journal/article/view/1423 |
| work_keys_str_mv | AT nmprotas hepatocentricapproachtoachievingcompensationofdiabetesmellitusinpeoplewithnonalcoholicsteatohepatitis AT iokostitska hepatocentricapproachtoachievingcompensationofdiabetesmellitusinpeoplewithnonalcoholicsteatohepatitis AT mvbielinskyi hepatocentricapproachtoachievingcompensationofdiabetesmellitusinpeoplewithnonalcoholicsteatohepatitis |